Welcome to the 2022 ASPHO Conference

We’re proud to be a part of the pediatric hematology-oncology community

May 6

3:45 – 5:15 p.m.

Sneha Ramakrishna, MD

• Adoptive Cellular Therapy for Solid Tumors: Prior Experience, Challenges, and Potential for the Future

6:00 – 7:30 p.m.

Meet and Greet at the Stanford Children’s Health Booth (#501)
Meet some of our faculty and fellows and learn more about our research.

May 7

8:45 – 9:45 a.m.

Kathleen Sakamoto, MD, PhD

• Supporting Each Other: The Role of Diversity and Inclusion in Cultivating Value and Appreciation

Papers and posters

Raul Montiel-Esparza, MD

• Potential Biomarkers of Acute GVHD in Alpha/Beta T-Cell/B-Cell Depleted HSCT Pediatric Recipients

Chris Severyn, MD, PhD

• A Pilot Study of Gut Decontamination and the Risk of Bloodstream Infections During Pediatric Allogeneic Hematopoietic Cell Transplantation

Visit our booth

Visit us at booth #501 to meet our team and learn more about our programs, including our fellowship program.

Clinical trials

We’re working to bring cutting-edge cures from bench to bedside. Our only-at-Stanford trials include:

• GD2 CAR T Cells for Diffuse Intrinsic Pontine Gliomas (DIPG) and Spinal Diffuse Midline Glioma (DMG)
• Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory CD19/CD22 B Cell Malignancies
• Phase IB Clinical Trial of Autologous CD22 CAR T cells in Children and Young Adults with Recurrent or Refractory B Cell Malignancies
• Palbociclib in Combination with Chemotherapy in Pediatric Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
• Phase I Study of Autologous CD4^LVFOXP3 in Participants with IPEX Syndrome
• TCRab+T-CellCD19+B Depleted Hematopoietic Grafts and a Reduced-Intensity Preparative Conditioning Regimen Containing JSP191 to Achieve Engraftment and Blood Reconstitution in Patients with Fanconi Anemia
• Allogenic Hematopoietic Stem Cell Transplantation From an HLA-Partially Matched Related or Unrelated Donor After TCR αβ+ T Cell/CD19+ B Cell Depletion in Children and Young Adults Affected by Malignant or Non-Malignant Hematological Disorders
• A Study of T-allo10 Infusion After HLA-Partially Matched Related or Unrelated TCR αβ+ T Cell/CD19+ B-Cell Depleted Allogenic Hematopoietic Stem Cell Transplantation in Children and Young Adults Affected by Hematologic Malignancies
• Use of T-allo10 Cell Infusions Combined with Mismatched Related or Unrelated Donor Hematopoietic Stem Cell Transplantation for Hematological Malignances 

See our full list of Phase I and II clinical trials and call (650) 497-8953 to learn more.